Nyxoah (NYXH)
NASDAQ:NYXH
Earnings Data
Report Date
May 19, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.59Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights a successful regulatory milestone (FDA approval), clear early commercial traction in the U.S., rapid revenue acceleration (+122% FY 2025) and healthy gross margins (63-64%), supported by reimbursement progress and salesforce expansion. However, the company is investing heavily to commercialize—resulting in a materially larger full-year operating loss (+~42%)—and faces near-term cash burn (≈EUR 20M/quarter) with limited runway into early 2027 unless revenue ramps as guided. Reimbursement coding and lack of disclosed implant counts create some execution and transparency risks. On balance, the strong growth, product differentiation, and reimbursement wins outweigh the financial and operational risks in the near term.Company Guidance
U.S. FDA Approval and Commercial Launch
Genio received FDA approval on August 8, 2025, and Nyxoah executed its first full U.S. commercial quarter in Q4 2025 with an established U.S. commercial team and launch plan.
Strong Revenue Growth
Full-year 2025 net revenue was EUR 10.0 million versus EUR 4.5 million in 2024, representing 122% year-over-year growth; Q4 2025 net revenue was EUR 5.6 million versus EUR 1.3 million in Q4 2024 (approximately +331% YoY).
U.S. Launch Contribution
U.S. commercialization was a primary driver in Q4 2025, contributing approximately EUR 3.5 million of net revenue in the quarter (company also referenced ~$4.5 million of U.S. revenue in Q4 in commentary).
High Gross Margins
Gross margin of 64% in Q4 2025 and 63% for full-year 2025, with management expecting modest margin improvement in 2026 and a step-function improvement toward ~70% after Genio 2.2 and lower disposable patch costs in 2027.
Commercial Traction and Training Metrics
As of Dec 31, 2025, Nyxoah had trained 145 surgeons across 125 targeted high-volume accounts, submitted 120 value analysis committee (VAC) requests and received 57 VAC approvals with no rejections to date.
Reimbursement Progress
Genio secured reimbursement consistency across commercial payers (~90% of business) and Medicare (~10%); CMS established interim C-codes in Feb 2026 and set a hospital outpatient facility fee of $31,526 for the Genio C-code, creating parity with competitor facility reimbursement.
Sales Force Expansion and Account Coverage
Salesforce increased from 25 reps at launch to 40 reps (adding 15 reps and 3 sales directors in Q1 2026), expanding coverage from ~125 to ~200 of the top 400 HGNS accounts and accelerating account outreach.
International and Operational Progress
International markets (notably Germany) continued to contribute revenue and Germany achieved profitability; management is expanding manufacturing to support scale and improve gross margins.
Near-Term Revenue Growth Outlook
Company guidance expects U.S. net revenue to grow ~25% sequentially in both Q1 and Q2 2026, driven by additional surgeon training, VAC approvals and adoption.
NYXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NYXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $3.09 | $3.08 | -0.32% |
Nov 13, 2025 | $5.31 | $5.00 | -5.84% |
Aug 18, 2025 | $6.57 | $6.27 | -4.57% |
May 14, 2025 | $5.78 | $6.06 | +4.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nyxoah (NYXH) report earnings?
Nyxoah (NYXH) is schdueled to report earning on May 19, 2026, After Close (Confirmed).
What is Nyxoah (NYXH) earnings time?
Nyxoah (NYXH) earnings time is at May 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NYXH EPS forecast?
NYXH EPS forecast for the fiscal quarter 2026 (Q1) is -0.59.